Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Consent Agenda Removal of PrismaSATE® PrismaSATE® will be
Document related concepts
Transcript
Consent Agenda Removal of PrismaSATE® PrismaSATE® will be removed from the adult formulary and will be interchanged with PrismaSOL® solutions. Order sets for Prismaflexbased Adult Continuous Replacement Therapy (CRRT – Non Transplant) in the Neuro/MICU population were recently approved and implemented, which necessitated addition of PrismaSOL® solutions to the Adult/MUH-MLBH formulary (affecting MUH and 7-East/Transplant ICU). This interchange will allow consolidation of solution supply, decrease the likelihood of dispensing errors, and enable use of products in a fashion consistent with FDA-labeling for IV/replacement fluid use. March 2016 Special Interest Articles Consent Agenda Annual formulary review Approved Order Sets and Power Plans Policy Reviews Med Use Policy Update Daptomycin/Linezolid Daptomycin/Linezolid prescriber documentation forms with revised FDA Alerts criteria were approved. For daptomycin, the requirements include: (1) Drug Shortage Report the patient’s primary source of infection is not pneumonia,(2) no other first-line treatment options (no documented allergic reaction) are Upcoming Meeting available, and (3) a documented or suspected MRSA / MRSE or VRE infection (abcess, bacteremia, or endocarditis). For linezolid, criteria will include: (1) a documented or suspected VRE infection, or (2) MRSA/MRSE abscess, skin/skin structure infections, or pneumonia, and (3) no other first-line treatment options (no Contributing Writer: documented allergic reaction) are available. Any other reason for prescribing daptomycin or linezolid requires an ID Dagny Ulrich, PharmD Editor: consult (or pulmonary consult at Olive Branch). Tifany Derheimer, PharmD Annual Formulary Review The following discontinued medications were removed from the adult formulary: Erythromycin Ethylsuccinate and Sulfisoxazole oral suspension,Tetracaine 2% topical solution, and Vasolex ointment. Add to the adult formulary: Venelex ointment (recommended by system wound care nurses to replace Vasolex) Recent FDA-approved HIV medications including: Prezcobix (Darunavir and Cobicistat) Evotaz (Atazanavir and Cobicistat) Genvoya (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) References: LexiComp Micromedex www.fda.gov www.ashp.org All P&T decisions and actions described herein have been approved by the Medical Executive Committee Approved Order Sets/Power Plans The following ordersets/plans were approved: New Order Sets/Power Plans/Protocols a. Anesthesia Low Dose Ketamine for Post Op Pain Edited Order Sets/Power Plans/Protocols a. MED Sepsis 6 Hour Bundle Plan b. MED Severe Sepsis 6 Hour Bundle Plan c. CROSS Heparin Non Protocol Infusion Orders d. MECH Admit Plan e. PULM Bronchoscopy Pre Procedure Plan f. HEM BMT Transplant Admit g.Hypothermia Orders Policy Reviews The following policies were reviewed and approved by the Pharmacy and Therapeutic Committee: Scope of Service Policy-Pharmacy, Medication related devices brought from home, and Unapproved Abbreviation Policy Med Use Policy Updates: Low Dose Ketamine for Management of Post-Op pain This policy will allow the use of low dose ketamine for postoperative pain control in adult patients as an adjunct to opioid medications. Ordering and management will be limited to the acute pain service (anesthesia). Patients receiving low-dose ketamine intravenous infusions will have therapy initiated and maintained in the following areas of University and Germantown hospitals only: PACU, Step Down, ICU, and 4 West (Germantown). Use is limited to patients who are less than or equal to 70 years of age, opioid tolerant and undergoing complex spine surgery, total joint/orthopedic surgery or complex gastrointestinal surgery. The Anesthesia Low Dose Ketamine for Post Op Pain Powerplan includes the ketamine, dosing of ketamine, monitoring and assessment, and adjunctive therapies. FDA Alerts: Baxter IV Solutions (Select Lots): Drug Safety Communication - Recall - Potential for Leaking Containers and Particulate Matter Drug Shortage Report: PCAs (Hydromorphone and Morphine PCA) were recently removed from the list. Upcoming Meetings for 2016: April 7th Meeting time: 12 noon-1 PM Meeting Locations: University: 1 Thomas Auditorium Germantown: Pavilion Classroom 1 North: Meeting Room 1 South: Conference Room B Olive Branch: Methodist Olive Branch Board Room, Room 1215
